Global DVT Screening and Treatment Devices Market Size By Type (Imaging Modalities, Intravascular Ultrasound), By Application (Hospitals and Clinics, Others), By Region, And Segment Forecasts, 2023 to...

lobal DVT Screening and Treatment Devices Market Report Description

The Global DVT (Deep Vein Thrombosis) Screening and Treatment Devices Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 4.3 billion by 2031, growing at a CAGR of 9.3% during the forecast period from 2023 to 2031. This growth is primarily driven by the increasing prevalence of venous thromboembolism (VTE), rising awareness about early diagnosis, and advancements in non-invasive screening technologies. The expanding geriatric population, along with sedentary lifestyles and rising incidence of chronic conditions such as cancer and obesity, are major contributing factors to the growing need for efficient DVT screening and treatment solutions.

Drivers:

1. Rising Prevalence of DVT and VTE Disorders:

The growing incidence of DVT and related thrombotic events due to aging populations, long-duration travel, and surgical procedures is fueling the demand for early screening and intervention tools.

2. Technological Advancements in Diagnostic Devices:

Innovations such as portable ultrasound systems, wearable compression devices, and AI-integrated diagnostic platforms are enhancing detection accuracy and expanding device accessibility.

3. Increasing Awareness and Preventive Healthcare Measures:

Government and healthcare organizations are actively promoting public health campaigns and risk assessment protocols, which is leading to higher screening rates.

Restraints:

1. High Cost of Advanced Treatment Devices:

While technological innovations improve outcomes, the associated high cost limits access in low-income and resource-constrained settings.

2. Limited Penetration in Developing Countries:

Infrastructural deficiencies, lack of awareness, and inadequate reimbursement frameworks are impeding widespread adoption in emerging markets.

Opportunity:

1. Growing Demand in Home Healthcare Settings:

The increasing preference for home-based care, particularly among elderly and post-surgical patients, is creating significant demand for portable DVT screening and therapeutic devices.

2. Integration with Digital Health Platforms:

The incorporation of smart diagnostics and digital monitoring through connected health platforms provides real-time insights and personalized treatment, opening new revenue streams for manufacturers.

Market by System Type Insights:

Based on system type, the Ultrasound-Based DVT Screening Devices segment dominated the market in 2023. These systems offer real-time imaging, high accuracy, and non-invasive diagnostics, making them the most preferred method in clinical settings. However, Portable Compression Therapy Devices are projected to witness the fastest growth owing to increasing use in outpatient and home care environments.

Market by End-use Insights:

In terms of end-use, Hospitals and Clinics led the global market in 2023, contributing to over 50% of the revenue share. This is attributed to the high patient inflow, availability of trained professionals, and comprehensive diagnostic capabilities. Meanwhile, the Homecare Settings segment is expected to grow significantly during the forecast period due to the rise in remote monitoring and wearable therapy device usage.

Market by Regional Insights:

Geographically, North America held the largest market share in 2023, driven by well-established healthcare infrastructure, favorable reimbursement policies, and rising incidence of thrombotic disorders. Asia-Pacific is expected to register the fastest growth rate during the forecast period, supported by increasing healthcare investments, improving diagnostic capabilities, and growing public health initiatives in countries like China and India.

Competitive Scenario:

Key players in the Global DVT Screening and Treatment Devices Market include Philips Healthcare, GE HealthCare, Boston Scientific Corporation, Stryker Corporation, Zimmer Biomet, Arjo AB, Breg Inc., and Enovis Corporation. Companies are focusing on expanding their product portfolios through R&D investments, mergers & acquisitions, and technological collaborations.

Key Market Developments:

In 2023, Philips introduced a portable ultrasound solution enhanced with AI for rapid DVT screening in emergency and outpatient settings.

Boston Scientific acquired a start-up specializing in wearable DVT prevention systems in 2024 to enhance its presence in the homecare segment.

GE HealthCare launched a cloud-based diagnostic suite in 2025, integrating real-time vascular imaging with AI-assisted analytics.

Scope of Work – Global DVT Screening and Treatment Devices Market

Report Metric Details

Market Size (2023) USD 2.1 billion

Projected Market Size (2031) USD 4.3 billion

CAGR (2023–2031) 9.3%

Market Segments By System Type (Ultrasound, Compression Devices), End-use (Hospitals, Homecare), Region

Growth Drivers Rising DVT prevalence, technological advancements, increasing preventive healthcare initiatives

Opportunities Homecare adoption, integration with digital health platforms

FAQs:

1) What is the current market size of the Global DVT Screening and Treatment Devices Market?

The market size was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global DVT Screening and Treatment Devices Market?

The major driver is the increasing prevalence of DVT and the push for early diagnosis and preventive screening.

3) Which is the largest region during the forecast period in the Global DVT Screening and Treatment Devices Market?

North America is expected to remain the largest regional market during the forecast period.

4) Which segment accounted for the largest market share in the Global DVT Screening and Treatment Devices Market?

The Ultrasound-Based DVT Screening Devices segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global DVT Screening and Treatment Devices Market?

Key players include Philips Healthcare, GE HealthCare, Boston Scientific, Stryker, Zimmer Biomet, and Arjo AB.

Let me know if you'd like this content exported to a Word or PDF document.